Tag: Heart / Stroke-Related: Heart Attack

Increasing neighborhood marginalization linked to higher rates of mortality beginning at 30 days after discharge

Total adverse events of heart failure or all-cause mortality were reduced with empagliflozin, regardless of kidney function

Risk for major adverse cardiac and cerebrovascular events lower compared with aspirin monotherapy for patients who undergo PCI and discontinue DAPT

In a recent study, one-year MACE incidences were 1.79, 2.58, and 4.03 per 100 patient-years for early, late, and no ezetimibe added to statins

Increased risk seen for adverse cardiovascular events, including myocardial infarction, stroke, heart failure, mortality

Increased risk seen with use of combined pill, progestin-only pills, combined vaginal ring, patch, and progestin-only implant

No significant difference seen in composite of 30-day mortality or MI; cardiac death at 30 days increased with restrictive strategy

Estimated unadjusted cumulative incidence did not differ between long-term care residents who were deprescribed or continued antihypertensives

Findings seen in patients following myocardial infarction

Findings seen for individuals undergoing revascularization after non-ST-segment elevation myocardial infarction